Indian government caps companies’ royalty fees for GM seeds, adds other restrictions on sales

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.

The Indian government has capped royalty fees payable to Monsanto Co. and other providers of genetically modified (GM) seed technology and barred them from denying a licence to any local company.

According to a notification issued on 18 May, for any GM trait commercialized in India, the technology provider cannot charge a royalty that exceeds 10% of the maximum sale price of the seeds, which is fixed by the government every year.

The cap of 10% will apply for the first five years. From the sixth year on, the royalty will decrease by 10% a year.

And the technology provider cannot refuse a licence to any eligible Indian seed company.

Read full, original post: Government tightens rules for GM seed technology providers

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

vax-misinformation-main
Facts & Fallacies Podcast: Limit free speech to blunt social media misinfo?
Picture1
The FDA couldn’t find a vaccine safety crisis, so it buried its own research
ChatGPT-Image-Apr-16-2026-02_56_53-PM
Financial incentives, over diagnosis, and weak oversight: Autism claims are driving up Medicare costs
ChatGPT-Image-May-12-2026-11_27_01-AM-2
AI likely to improve health care, research shows—but not for blacks and ethnic minorities
modi visit sikkim
Viewpoint: Indian PM wants farmers to switch to 50% organic. It would take at least 10 years, likely won’t work, and isn’t more sustainable
ChatGPT-Image-May-7-2026-12_32_36-PM
Viewpoint: The state of U.S. vaccine policy? Dismal nationally, but some states are stepping up.
Screenshot-2026-04-22-at-12.21.32-PM
Viewpoint: Why the retracted Monsanto glyphosate study doesn’t change the science—the world’s most popular herbicide is safe 
Screenshot-2026-05-19-at-11.23.34-AM
West-originated vaccine disinformation sparks murders of health care workers across Africa
Screenshot-2026-04-13-at-1.39.26-PM
Viewpoint: ‘Safer for children?’ Stonyfield yogurt under fire for deceptive organic marketing
Screenshot-2026-05-18-at-12.57.12-PM
Viewpoint—‘Technology is pulling us apart’: Environmental, political, and economic
ChatGPT-Image-May-12-2026-08_39_41-PM
GLP podcast: Big Pharma, Big Ag, Big Food—health harming industries or life-saving innovators?
newborn infant baby mother
Sharp rise in number of parents refusing newborn vitamin K shots, putting babies at 81-fold higher risk of severe bleeding
ChatGPT-Image-May-20-2026-04_53_21-PM-2
Viewpoint: Doctors can fight health misinformation — if hospitals let them
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.